{"id":3513,"date":"2026-09-28T09:00:00","date_gmt":"2026-09-28T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3513"},"modified":"2026-09-29T19:11:13","modified_gmt":"2026-09-29T23:11:13","slug":"brelovitug-clears-the-first-pivotal-hdv-gate","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3513","title":{"rendered":"Brelovitug Clears the First Pivotal HDV Gate"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Mirum Pharmaceuticals<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 Results<\/p>\n

Modality<\/strong><\/p>\n

Monoclonal Antibody<\/p>\n

Asset<\/strong><\/p>\n

Brelovitug<\/p>\n

Target<\/strong><\/p>\n

Hepatitis B Surface Antigen<\/p>\n

Disease Area<\/strong><\/p>\n

Chronic Hepatitis Delta Virus Infection<\/p>\n

Summary<\/h4>\n

Mirum reported that brelovitug met the Phase 3 AZURE-1 primary endpoint in treatment-naive chronic hepatitis delta virus infection. At week 24, 56% of patients receiving 300 mg weekly and 45% receiving 900 mg every four weeks achieved both virologic response and alanine-aminotransferase normalization, versus 0% with delayed treatment; both comparisons had p<0.0001. No grade 3 or worse or serious adverse events occurred in either active arm through week 24. The signal is positive, while full subgroup, durability and clinical-outcome data remain pending.<\/p>\n

AZURE-1 randomized 153 Phase 3 participants 2:2:1 to weekly brelovitug, every-four-week brelovitug or a 24-week delayed-start control. Virologic response rates were 86% and 85% in the active arms versus 0%; HDV RNA was below quantification in 25% and 26%, and target-not-detected in 17% in each active arm. ALT normalization reached 63% and 54%, compared with 0%.<\/p>\n

Any adverse events occurred in 45.8% of weekly recipients, 61.5% of every-four-week recipients and 27.6% of delayed controls. Injection-site reactions were 10.2% and 18.5%; flu-like symptoms were 5.1% and 10.8%. No active-arm participant had a grade 3 or worse adverse event, serious event or drug discontinuation. In the earlier 53-patient Phase 2b cohort, viral suppression deepened through week 48. AZURE-4 is the second pivotal study and is expected to read out in the fourth quarter of 2026. Mirum plans a U.S. BLA in the first half of 2027. Brelovitug has FDA Breakthrough Therapy designation and EMA PRIME and orphan designations.<\/p>\n

Deep Analysis<\/h4>\n

Brelovitug is a fully human antibody against hepatitis B surface antigen intended to neutralize HBV and HDV virions and clear HBsAg-containing subviral particles. The combined endpoint requires antiviral activity plus normalization of a marker of hepatocellular injury. That is more informative than RNA decline alone, although it does not directly establish prevention of cirrhosis, decompensation, cancer or death.<\/p>\n

The weekly dose produced a numerically higher combined-response rate and fewer local and flu-like events than the every-four-week regimen, while virologic response was similar. Without a formal active-arm comparison, exposure-response and adherence data, this cannot establish superiority. Long-term chronic treatment also raises questions about antidrug antibodies, breakthrough viremia and durability after discontinuation.<\/p>\n

Two interpretations remain plausible. The constructive view is that a single-agent antibody can control both virus and inflammation with an attractive safety profile in a disease lacking U.S.-approved therapy. The competing view is that biomarker responses may not translate into durable clinical benefit and the second pivotal study could reveal weaker performance or subgroup heterogeneity. Replication in AZURE-4, sustained RNA suppression, HBsAg kinetics and liver-event follow-up would upgrade the thesis; discordant replication, resistance or emerging immunogenicity would downgrade or falsify it.<\/p>\n

Company and Product Background<\/h4>\n

Mirum Pharmaceuticals focuses on rare liver and genetic diseases. Hepatitis delta virus requires hepatitis B surface antigen for replication and accelerates progression to cirrhosis, liver cancer and liver-related death. Brelovitug is a pan-genotypic anti-HBsAg IgG1 monoclonal antibody designed to neutralize and remove HBV and HDV virions and deplete HBsAg-rich subviral particles. Mirum owns worldwide rights.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Pivotal efficacy: both dose arms met the combined virologic and ALT-normalization endpoint versus delayed treatment.<\/li>\n
  • Safety signal: no active-arm grade 3 or worse adverse events, serious events or treatment discontinuations through week 24.<\/li>\n
  • Dose signal: weekly dosing produced the higher combined-response rate, while both schedules achieved similar virologic response.<\/li>\n
  • Regulatory path: AZURE-4 is the remaining pivotal gate before a planned first-half 2027 BLA.<\/li>\n
  • Decisive next evidence: independent AZURE-4 replication, full subgroup results, immunogenicity and longer-term liver outcomes.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    AZURE-1 is a high-strength positive signal because it pairs a randomized pivotal endpoint with a favorable early safety profile in a severe infection with no approved U.S. therapy. The result does not yet prove disease modification at the level of cirrhosis or survival, and one additional pivotal study remains. The weekly schedule currently looks more persuasive, but formal regimen selection requires complete exposure, adherence and comparative analyses.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high for the randomized topline data. Confidence in Interpretation: moderate-high for antiviral and biochemical activity and moderate for long-term clinical benefit. Red-team conclusion: a successful combined biomarker endpoint is not yet proof of fewer liver complications, and AZURE-4 remains a material replication risk.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Mirum reported that brelovitug met the Phase 3 AZURE-1 primary endpoint in treatment-naive chronic hepatitis delta virus infection. At week 24, 56% of patients receiving 300 mg weekly and 45% receiving 900 mg every…<\/p>\n","protected":false},"author":1,"featured_media":3520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[891,890,610],"class_list":["post-3513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-brelovitug","tag-hepatitis-delta-virus","tag-mirum-pharmaceuticals"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3513"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3513\/revisions"}],"predecessor-version":[{"id":3525,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3513\/revisions\/3525"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3520"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}